Who is sponsoring NCT07396493?

NCT07396493 is sponsored by Shanghai Zhongshan Hospital.

What drugs are being tested in NCT07396493?

Interventions in NCT07396493: Intra-operative application of LAAC.

What condition does NCT07396493 study?

NCT07396493 studies Non-valvular Atrial Fibrillation (NVAF), High Risk of Stroke.

Is NCT07396493 still recruiting?

NCT07396493 is currently not yet recruiting. Last updated 9 February 2026.

Last reviewed 2026-02-09 · How we verify

NCT07396493: AnchorMan-NVAF

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Prospective, Single-arm Study Evaluating the Endothelialization Effect and Timeline of AnchorMan® Left Atrial Appendage Occluder in Non-valvular Atrial Fibrillation Patients at High Risk of Stroke

Not yet recruiting NA Last updated 9 February 2026

What this trial tests

NA trial testing Intra-operative application of LAAC in Non-valvular Atrial Fibrillation (NVAF) in 306 participants. Not yet recruiting.

Timeline

8 February 2026

Primary endpoint
12 June 2027

31 December 2027

Quick facts

Lead sponsor	Shanghai Zhongshan Hospital
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	306
Start date	8 February 2026
Primary completion	12 June 2027
Estimated completion	31 December 2027

Drugs / interventions tested

Intra-operative application of LAAC

Conditions studied

Non-valvular Atrial Fibrillation (NVAF) — all drugs for Non-valvular Atrial Fibrillation (NVAF) →
High Risk of Stroke — all drugs for High Risk of Stroke →

Sponsor

Shanghai Zhongshan Hospital

Who can join

18 Days and older, any sex, with Non-valvular Atrial Fibrillation (NVAF) or High Risk of Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to evaluate the endotheliation efficacy of the AnchorMane® Left Atrial Appendage Occluder in non-valvular atrial fibrillation patients at high stroke risk. It investigates the rate of complete endotheliation of the occluder at 6 months post-procedure using routine cardiac CTA, providing additional data for clinical application and further product development. Study Size and Duration: This study plans to enrol1 306 patients. All participants will undergo follow up immediately after occluder implantation, prior to discharge or within 7 days post-procedure, at 1 month post-procedure, at 3 months post-procedure,and at 6 months post-procedure. The total study duration is projected to be 3 year. The expected duration of participation for each participant is approximately 6 months.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Non-valvular Atrial Fibrillation (NVAF)

Currently open trials in the same condition.

NCT07385599 — FIM Study of the LAmbre™ II LAA Occluder in Non-Valvular AF Patients · NA · active not recruiting
NCT06725355 — To Compare the Pharmacokinetics and Safety After a Single Dose Administration of IN-G00002 and IN-R00002 in Healthy Adul · Phase 1 · active not recruiting

Other Shanghai Zhongshan Hospital trials

Trials by the same sponsor.

NCT07353476 — Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC · Phase 2 · not yet recruiting
NCT07508956 — Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric · Phase 3 · not yet recruiting
NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
NCT07531368 — BBAP With CS Mapping Guidance · NA · not yet recruiting
NCT07501104 — Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07396493 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Zhongshan Hospital
Last refreshed: 9 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07396493.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing